var data={"title":"Clinical features and diagnosis of leptomeningeal metastases from solid tumors","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical features and diagnosis of leptomeningeal metastases from solid tumors</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/contributors\" class=\"contributor contributor_credentials\">Alexis Demopoulos, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/contributors\" class=\"contributor contributor_credentials\">Lisa M DeAngelis, MD, FAAN, FANA</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/contributors\" class=\"contributor contributor_credentials\">Jay S Loeffler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/contributors\" class=\"contributor contributor_credentials\">April F Eichler, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 26, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Leptomeningeal metastases (LM; carcinomatous meningitis) are a rare but frequently devastating complication of advanced cancer. Patients can present with a broad range of signs and symptoms due to involvement of multiple areas of the craniospinal axis. Diagnosis often requires a high index of suspicion and is confirmed by neuroimaging and cerebrospinal fluid (CSF) analysis.</p><p>The pathophysiology, clinical manifestations, and diagnosis of LM from solid tumors will be reviewed here. The treatment of LM and leptomeningeal involvement in hematologic malignancies, especially large cell lymphomas and acute leukemias, are discussed separately. (See <a href=\"topic.htm?path=treatment-of-leptomeningeal-metastases-carcinomatous-meningitis\" class=\"medical medical_review\">&quot;Treatment of leptomeningeal metastases (carcinomatous meningitis)&quot;</a> and <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-secondary-central-nervous-system-lymphoma#H7\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of secondary central nervous system lymphoma&quot;, section on 'Leptomeningeal metastasis'</a> and <a href=\"topic.htm?path=involvement-of-the-central-nervous-system-with-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Involvement of the central nervous system with acute myeloid leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>LM are diagnosed in approximately 5 percent of patients with metastatic cancer [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1-3\" class=\"abstract_t\">1-3</a>], but undiagnosed or asymptomatic involvement is more common [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/4-10\" class=\"abstract_t\">4-10</a>]. At autopsy, the frequency of LM averages 20 percent and is much higher with some tumor types [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/2,11,12\" class=\"abstract_t\">2,11,12</a>]. Coexisting brain metastases are present in 50 to 80 percent of patients in modern series [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/13-17\" class=\"abstract_t\">13-17</a>].</p><p>The most common solid tumors giving rise to LM are breast cancer (12 to 35 percent), lung cancer (10 to 26 percent), melanoma (5 to 25 percent), gastrointestinal malignancies (4 to 14 percent), and cancers of unknown primary (1 to 7 percent) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1-3,13\" class=\"abstract_t\">1-3,13</a>]. In women with breast cancer, infiltrating lobular carcinoma has a particular predilection to metastasize to the leptomeninges [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/18-20\" class=\"abstract_t\">18-20</a>]. Primary brain tumors, including low- and high-grade astrocytomas, medulloblastomas, ependymomas, pineoblastomas, and oligodendrogliomas, can infiltrate the leptomeninges or disseminate along cerebrospinal fluid (CSF) pathways [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p>The development of LM may also be influenced by treatment:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Improved treatment strategies for systemic cancers that lead to longer survival (eg, <a href=\"topic.htm?path=trastuzumab-including-biosimilars-of-trastuzumab-drug-information\" class=\"drug drug_general\">trastuzumab</a> in HER2-positive breast cancer) may increase the risk of developing central nervous system (CNS) metastases, including LM [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/23-26\" class=\"abstract_t\">23-26</a>]. In some cases, the blood-CSF barrier likely creates a sanctuary site where malignant cells are shielded from systemic therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgical resection of brain metastases from the posterior fossa but not the supratentorial compartment has been associated with increased risk of subsequent LM, presumably due to spillage of malignant cells into the CSF [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/27-29\" class=\"abstract_t\">27-29</a>]. The risk appears to be greater after piecemeal resection of metastases compared with en bloc resections for both posterior fossa and supratentorial brain metastases [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/30-32\" class=\"abstract_t\">30-32</a>].</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are three membranes surrounding the brain and spinal cord: the dura mater, the arachnoid, and the pia mater. The dura mater is also referred to as the pachymeninges, and the inner two layers are called the leptomeninges. The subarachnoid space lies between the arachnoid and pia mater and contains the cerebrospinal fluid (CSF) and penetrating arteries supplying the brain parenchyma. Tumor involvement of the leptomeninges, which is distinguished from tumor involving the dura, is associated with spread of malignant cells throughout the subarachnoid space. </p><p>The total CSF volume in adults is approximately 140 mL, and the entire volume is replaced more than five times daily. The physiology of CSF formation and flow is discussed in detail elsewhere. (See <a href=\"topic.htm?path=cerebrospinal-fluid-physiology-and-utility-of-an-examination-in-disease-states\" class=\"medical medical_review\">&quot;Cerebrospinal fluid: Physiology and utility of an examination in disease states&quot;</a>.)</p><p>Tumor cells can gain access to the CSF in several ways (<a href=\"image.htm?imageKey=ONC%2F78434\" class=\"graphic graphic_figure graphicRef78434 \">figure 1</a>). Hematogenous spread via the arachnoid vessels or direct extension from the brain parenchyma are probably the most common means. Other possible routes include spread from choroid plexus metastases into the CSF; direct extension from vertebral, subdural, or epidural metastases; retrograde invasion along peripheral or cranial nerves to the subarachnoid space; and rare de novo tumors arising in the meninges, including lymphoma, melanoma, and several sarcomas (eg, malignant peripheral nerve sheath tumors).</p><p>The clinical manifestations of LM can be caused by several different pathophysiologic mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mass effect, due to invasion of the leptomeninges and associated inflammation, occluding CSF flow; this can lead to hydrocephalus or, less often, increased intracranial pressure (ICP) without hydrocephalus.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cranial nerve and spinal nerve root dysfunction, caused by direct tumor involvement.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Invasion of the brain parenchyma by tumor cells, usually via the Virchow-Robin spaces. Symptoms are then caused by interference with the cerebrovascular circulation or competition with brain cells for essential metabolites, including glucose and oxygen.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disruption of the blood-brain barrier, causing cerebral edema.</p><p/><p>The most common sites of gross tumor involvement are the base of the brain (basilar cisterns or posterior fossa), the sylvian fissures, and the cauda equina, probably due to the relatively slow flow of CSF through these areas. Tumor cells may also invade the spinal or cranial nerves, cerebral cortex, or spinal cord via the Virchow-Robin spaces (<a href=\"image.htm?imageKey=ONC%2F65372\" class=\"graphic graphic_picture graphicRef65372 \">picture 1</a>).</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with LM present relatively acutely, with symptoms emerging over days to weeks. Most patients have multifocal neurologic signs and symptoms, indicative of multilevel involvement. Neuroimaging typically shows linear <span class=\"nowrap\">and/or</span> nodular enhancement of the leptomeninges, cranial nerves, and spinal nerve roots, especially the cauda equina. Cerebrospinal fluid (CSF) is usually abnormal, with elevated protein, increased numbers of lymphocytes, decreased glucose, and positive cytology. However, neuroimaging may be unrevealing and CSF can be normal, especially in patients with hematologic malignancies.</p><p class=\"headingAnchor\" id=\"H7302347\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multifocal involvement is a hallmark of leptomeningeal disease. Although patients may present with a single symptom, careful neurologic evaluation often reveals additional sites of neurologic dysfunction. As an example, a patient complaining of diplopia may have an absent Achilles tendon reflex. The specific clinical symptoms and signs vary, depending upon the site(s) of leptomeningeal invasion and the underlying pathophysiology (eg, hydrocephalus).</p><p>In a series of 150 patients with solid tumor LM, the most common presenting signs and symptoms were headache (39 percent), nausea and vomiting (25 percent), leg weakness (21 percent), cerebellar dysfunction (17 percent), altered mental status (16 percent), diplopia (14 percent), and facial weakness (13 percent) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/13,33\" class=\"abstract_t\">13,33</a>]. In the same series, 34 percent of patients presented with symptoms localized to one compartment (cerebral, posterior fossa, or spine), 39 percent to two compartments, and 25 percent to all three. Only two patients (1 percent) with solid tumor LM were asymptomatic at the time of diagnosis. </p><p class=\"headingAnchor\" id=\"H3980862348\"><span class=\"h3\">Headache</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Headache is the most common initial symptom of LM, present in 30 to 50 percent of patients [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1,13\" class=\"abstract_t\">1,13</a>]. Headache can be caused by increased intracranial pressure (ICP) or meningeal irritation, and it is sometimes difficult to distinguish the two. Asking about other symptoms associated with the headache can help:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nausea, vomiting, and dizziness accompanying headache suggest increased ICP, with or without associated hydrocephalus. The symptoms may worsen episodically in association with the development of plateau waves, often triggered by changes in body position (eg, sitting to standing). Funduscopic exam may show papilledema. (See <a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults\" class=\"medical medical_review\">&quot;Evaluation and management of elevated intracranial pressure in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Headache accompanied by neck pain or stiffness and exacerbated by head movements is more characteristic of meningeal irritation. In addition, pain with straight leg raising can also suggest spinal meningeal irritation. Nuchal rigidity may be present with or without headache. </p><p/><p class=\"headingAnchor\" id=\"H1008198\"><span class=\"h3\">Altered mental status</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptoms of confusion, forgetfulness, disorientation, subtle personality changes, <span class=\"nowrap\">and/or</span> lethargy, collectively referred to as encephalopathy or altered mental status, are common in patients with LM and can be secondary to diffuse cerebral dysfunction, hydrocephalus, seizures, or a combination. Encephalopathy in isolation, without other focal signs or symptoms, is uncommon.</p><p class=\"headingAnchor\" id=\"H1008206\"><span class=\"h3\">Cranial neuropathies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cranial neuropathies are caused by invasion of the cranial nerves within the subarachnoid space [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/11,34\" class=\"abstract_t\">11,34</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diplopia is the most common cranial nerve symptom of LM [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/4,14,33\" class=\"abstract_t\">4,14,33</a>]. Dysfunction of any of the cranial nerves supplying the extraocular muscles (ie, the oculomotor [III], trochlear [IV], or abducens [VI] nerves) can cause it. The history and exam can help localize diplopia to one or more cranial nerves. As an example, side-by-side or horizontal diplopia that is present on distance and lateral gaze is characteristic of an abducens palsy. (See <a href=\"topic.htm?path=overview-of-diplopia#H3\" class=\"medical medical_review\">&quot;Overview of diplopia&quot;, section on 'Presentation/history'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Facial pain, paresthesias, and numbness can indicate involvement of the trigeminal nerve. One specific form of facial numbness, the &quot;numb chin syndrome,&quot; can be a presenting symptom of LM disease, although it is more frequently due to bony mandibular metastases [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/11\" class=\"abstract_t\">11</a>]. In one series of 42 patients, numb chin syndrome was the presenting symptom of LM in 22 percent of cases and often preceded the diagnosis of recurrent cancer [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Facial weakness secondary to involvement of the facial nerve is manifested by weakness of both the upper face (ie, difficulty closing the eye completely, decreased eyebrow raise) and the lower face.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unilateral or bilateral sensorineural hearing loss is an infrequent presenting symptom of LM disease (&lt;5 percent) but becomes more common as the disease progresses.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dysarthria, dysphagia, or hoarseness can be symptoms of lower cranial nerve dysfunction.</p><p/><p class=\"headingAnchor\" id=\"H1008420\"><span class=\"h3\">Cerebellar dysfunction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gait instability, difficulty walking, dizziness, and falls referable to cerebellar dysfunction are present in approximately 20 percent of patients at diagnosis [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1,13\" class=\"abstract_t\">1,13</a>]. Both midline cerebellar symptoms (eg, gait ataxia) and lateral cerebellar symptoms (eg, limb dysmetria) can be seen.</p><p class=\"headingAnchor\" id=\"H1649165494\"><span class=\"h3\">Radiculopathy and cauda equina syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Spinal nerve root involvement may cause radicular pain, numbness, or muscle weakness in the anatomic distribution of the involved level (<a href=\"image.htm?imageKey=NEURO%2F53006\" class=\"graphic graphic_figure graphicRef53006 \">figure 2</a> and <a href=\"image.htm?imageKey=NEURO%2F50419\" class=\"graphic graphic_figure graphicRef50419 \">figure 3</a>). Most commonly, the roots of the cauda equina supplying the lower extremities, bowels, and bladder are affected, but roots in the thoracic and cervical spinal cord can also be involved. Cauda equina involvement can be manifested as leg pain, leg weakness or numbness, urinary incontinence or retention, <span class=\"nowrap\">and/or</span> an asymmetry of deep tendon reflexes. (See <a href=\"topic.htm?path=anatomy-and-localization-of-spinal-cord-disorders#H22\" class=\"medical medical_review\">&quot;Anatomy and localization of spinal cord disorders&quot;, section on 'Cauda equina syndrome'</a> and <a href=\"topic.htm?path=polyradiculopathy-spinal-stenosis-infectious-carcinomatous-and-inflammatory-nerve-root-syndromes\" class=\"medical medical_review\">&quot;Polyradiculopathy: Spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H178317791\"><span class=\"h3\">Seizures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Partial seizures with or without secondary generalization can be caused by cortical irritation from adjacent LM deposits, invasion of brain parenchyma, or local edema. Seizures have been reported in up to 25 percent of patients with LM [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1,14\" class=\"abstract_t\">1,14</a>].</p><p class=\"headingAnchor\" id=\"H4062728270\"><span class=\"h3\">Plateau waves</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dizziness, lightheadedness, presyncope, or even frank syncope, typically associated with positional changes (eg, sitting to standing), can be symptomatic of plateau waves in the setting of increased ICP or venous obstruction, even in the absence of headache. Evidence of increased ICP (eg, papilledema, hydrocephalus on imaging studies) should be sought. Frequently, ventricular enlargement is absent [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p class=\"headingAnchor\" id=\"H2330625590\"><span class=\"h3\">Other symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Focal cortical signs and symptoms such as hemiparesis, aphasia, or visual field defects are very unusual in LM, but can be caused rarely by invasion of brain parenchyma or focal ischemia [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/38\" class=\"abstract_t\">38</a>]. Panhypopituitarism or diabetes insipidus can result from leptomeningeal invasion of the pituitary stalk, although this is more common in leukemic than solid tumor LM.</p><p class=\"headingAnchor\" id=\"H7301458\"><span class=\"h2\">Neuroimaging studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gadolinium-enhanced magnetic resonance imaging (MRI) of the brain and spine often provides important evidence of LM. Although MRI probably is more sensitive (76 to 87 percent in multiple studies) than a single CSF specimen for cytology, it is less specific because a false-positive cytologic examination is rare [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/39-42\" class=\"abstract_t\">39-42</a>]. (See <a href=\"#H7301492\" class=\"local\">'Cytology'</a> below.)</p><p>In patients who cannot undergo MRI, computed tomography (CT) with contrast can demonstrate similar findings, albeit with lower sensitivity than MRI.</p><p class=\"headingAnchor\" id=\"H1357079994\"><span class=\"h3\">Brain MRI</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The typical brain MRI findings of LM include thin, diffuse leptomeningeal contrast enhancement following the contours of the gyri and sulci or multiple nodular deposits in the subarachnoid space. Common sites of abnormal leptomeningeal enhancement are the cerebellar folia (often best visualized on coronal postcontrast images) (<a href=\"image.htm?imageKey=ONC%2F88981\" class=\"graphic graphic_diagnosticimage graphicRef88981 \">image 1</a>), the cortical surface, and the basal cisterns, particularly along the ventral surface of the brainstem (<a href=\"image.htm?imageKey=RADIOL%2F87763\" class=\"graphic graphic_diagnosticimage graphicRef87763 \">image 2</a>). In addition, the cisternal segments of the cranial nerves may be abnormally thickened and enhancing (<a href=\"image.htm?imageKey=RADIOL%2F88877\" class=\"graphic graphic_diagnosticimage graphicRef88877 \">image 3</a>). High-resolution contrast-enhanced skull base MRI can sometimes show cranial nerve abnormalities that are not seen on routine MRI. Fluid-attenuated inversion recovery (FLAIR) images may show hyperintensity within the subarachnoid space, indicative of high protein content [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/43\" class=\"abstract_t\">43</a>]. </p><p>Any or all of these findings may be accompanied by ventriculomegaly in the absence of, or out of proportion to, the degree of sulcal enlargement (ie, hydrocephalus). In older adults and in patients previously treated with whole brain radiation, it can sometimes be difficult to distinguish hydrocephalus from ex vacuo enlargement of the ventricles. Imaging findings that suggest true hydrocephalus include abnormal periventricular T2 hyperintensity (suggesting transependymal CSF absorption) and sulcal effacement (<a href=\"image.htm?imageKey=RADIOL%2F87728\" class=\"graphic graphic_diagnosticimage graphicRef87728 \">image 4</a>).</p><p>Occasionally, frank leptomeningeal enhancement is not seen on MRI, but the presence of bulky subependymal disease or multiple small sulcal metastases suggests the diagnosis (<a href=\"image.htm?imageKey=ONC%2F88980\" class=\"graphic graphic_diagnosticimage graphicRef88980 \">image 5</a>). </p><p>In patients who are being treated with the antiangiogenic agent <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>, the diagnosis may be more difficult because neuroimaging features may be altered [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/44\" class=\"abstract_t\">44</a>]. Leptomeningeal enhancement may be minimal or absent, and the observed abnormalities may suggest vasculitis or small vessel vasculopathy.</p><p class=\"headingAnchor\" id=\"H1009758\"><span class=\"h3\">Spine MRI</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the spinal cord, MRI can show linear or nodular enhancement along the surface of the cord and linear or nodular enhancement of the cauda equina (<a href=\"image.htm?imageKey=RADIOL%2F58160\" class=\"graphic graphic_diagnosticimage graphicRef58160 \">image 6</a>). Occasionally, clumping of nerve roots at the cauda equina suggests the diagnosis even if contrast enhancement is not seen. Rarely, a leptomeningeal spinal tumor may obstruct CSF flow, resulting in hydrocephalus without any discrete tumor masses in the leptomeninges of the brain.</p><p class=\"headingAnchor\" id=\"H7301485\"><span class=\"h2\">Cerebrospinal fluid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The classic CSF findings of LM include a high protein concentration, low glucose concentration, lymphocytic pleocytosis, and positive cytology for malignant cells. Although most patients do not have all of these features, an entirely normal CSF examination is uncommon [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1,4,45,46\" class=\"abstract_t\">1,4,45,46</a>]. As an example, in one large series, only 5 of 104 patients with LM had completely normal basic CSF parameters; of these, four had breast cancer and one had leukemia. The most common CSF profile is a combination of high protein concentration and lymphocytic pleocytosis. (See <a href=\"topic.htm?path=cerebrospinal-fluid-physiology-and-utility-of-an-examination-in-disease-states\" class=\"medical medical_review\">&quot;Cerebrospinal fluid: Physiology and utility of an examination in disease states&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1009947\"><span class=\"h3\">Basic parameters</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Each one of the four basic CSF parameters (opening pressure, cell count with differential, total protein, and glucose) can be affected by the presence of LM.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An elevated opening pressure above 16 cm H<sub>2</sub>O is common when measured, but selection bias may be present in observational studies, as the decision to assess the pressure may be affected by the patient symptoms. In a study of 187 patients with LM at a single center over a two-year period, opening pressure was only measured in 32 patients, of whom 50 percent had values &gt;20 cm H<sub>2</sub>O [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/13\" class=\"abstract_t\">13</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mild elevation of the white blood cell count is seen in 50 to 60 percent of patients. The white cells are usually lymphocytes, although eosinophilia is seen with recurrent acute lymphoblastic leukemia and Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Xanthochromia is a result of bleeding into the CSF or elevation of the CSF protein &gt;150 <span class=\"nowrap\">mg/dL;</span> hemorrhage from LM is common with melanoma but rare in other tumors [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The CSF protein concentration is elevated (&gt;38 <span class=\"nowrap\">mg/dL)</span> in 60 to 80 percent of cases, mainly as the result of blood-brain barrier breakdown, although tumor protein production may also contribute [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1,13\" class=\"abstract_t\">1,13</a>]. Very high protein levels suggest blockage of CSF flow and may be associated with a paucity of CSF obtained during the procedure (&quot;dry tap&quot;).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The CSF glucose concentration is decreased (CSF:serum ratio &lt;0.6) in approximately 30 percent of cases, the result of either impaired transport or increased metabolism by tumors [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1,13\" class=\"abstract_t\">1,13</a>].</p><p/><p class=\"headingAnchor\" id=\"H7301492\"><span class=\"h3\">Cytology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The definitive diagnostic finding for LM is the cytologic identification of malignant cells within the CSF (<a href=\"image.htm?imageKey=ONC%2F55757\" class=\"graphic graphic_picture graphicRef55757 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/9,45\" class=\"abstract_t\">9,45</a>]. The specificity of CSF cytology is very high, since false-positive results are rare in the hands of experienced cytopathologists [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/45\" class=\"abstract_t\">45</a>].</p><p>By contrast, the sensitivity of cytology is only between 80 and 95 percent, and false-negative results can be a source of frustration for clinicians and patients, necessitating repeat lumbar punctures (LPs) and delaying therapy [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/4,45,49\" class=\"abstract_t\">4,45,49</a>]. Specific recommendations to minimize false-negative results include the following [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/45,46\" class=\"abstract_t\">45,46</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A minimum of 10 mL of CSF should be withdrawn with each sample solely for cytologic analysis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Specimens must be processed promptly, including immediate fixation in ethanol-based fixative for cytology. Specimens should not sit overnight before being fixed, even if refrigerated.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LP should be repeated if the initial cytology is negative but clinical suspicion is high, particularly if basic indices are abnormal (eg, high protein or pleocytosis).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CSF obtained closest to the site of symptoms (ie, intraventricularly or by cervical spine puncture under fluoroscopic guidance for cranial symptoms and LP for spinal root dysfunction) may have the highest yield [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/46\" class=\"abstract_t\">46</a>]. CSF drawn from an indwelling ventricular access device (eg, an Ommaya catheter) may yield very different results than CSF drawn from an LP.</p><p/><p>The optimal number of samples is uncertain. In a compilation of data from nine reports including 532 patients, the rates of positive cytology were 71, 86, 90, and 98 percent for one, two, three, or more than three samples per patient [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/45\" class=\"abstract_t\">45</a>]. However, these series varied according to the volume of CSF withdrawn, specimen processing, and whether or not intervening treatment had been administered. In most cases, a positive cytology can be obtained with two separate samplings totaling at least 30 mL, with little if any benefit gained from additional specimens.</p><p>Despite these measures, CSF cytology is persistently negative in as much as 20 percent of patients with clinically or radiographically unequivocal LM [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/13,45\" class=\"abstract_t\">13,45</a>]. The reason for negative CSF cytology in such patients is unclear; presumably, the malignant cells adhere to the leptomeninges rather than float in the CSF. In these cases, the diagnosis can be made in the appropriate clinical context by neuroimaging alone [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"#H5\" class=\"local\">'Diagnostic evaluation'</a> below.)</p><p>Immunohistochemical staining of cells in the cytologic specimen is sometimes possible and may provide diagnostic information or suggest the primary site in a patient with an unknown primary [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/50\" class=\"abstract_t\">50</a>]. </p><p class=\"headingAnchor\" id=\"H7301581\"><span class=\"h3\">Flow cytometry</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CSF flow cytometry or other molecular studies may be particularly valuable in diagnosing LM from hematologic malignancies. Flow cytometry is not generally indicated for the evaluation of suspected LM disease from solid tumors. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-secondary-central-nervous-system-lymphoma#H7\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of secondary central nervous system lymphoma&quot;, section on 'Leptomeningeal metastasis'</a> and <a href=\"topic.htm?path=involvement-of-the-central-nervous-system-with-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Involvement of the central nervous system with acute myeloid leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1010278\"><span class=\"h3\">Tumor markers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tumor markers (eg, CEA, PSA, CA-15-3, CA-125, and MART-1 and MAGE-3 in melanoma) may provide evidence for CSF dissemination of disease, even when serial cytologic evaluations are negative (<a href=\"image.htm?imageKey=ONC%2F81558\" class=\"graphic graphic_table graphicRef81558 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/2,49,51-61\" class=\"abstract_t\">2,49,51-61</a>]. Concentrations of CSF tumor markers that are more than 2 to 3 percent of simultaneous serum values are unlikely to be due to serum contamination or simple diffusion across the blood-brain barrier, unless the CSF albumin concentration is also very high (&gt;100 <span class=\"nowrap\">mg/dL),</span> indicating disruption of the blood-brain barrier. If the concentration of biochemical tumor markers within the CSF is greater than the serum concentration, then neoplastic meningitis is almost certain, even in the face of negative cytology.</p><p>Novel biochemical markers implicated in tumor invasion, angiogenesis, and metastasis (eg, vascular endothelial growth factor, matrix metalloproteinases, and lipid-associated sialic acid) are promising diagnostically but more data are needed, and they are not available for routine clinical care [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/61-66\" class=\"abstract_t\">61-66</a>].</p><p class=\"headingAnchor\" id=\"H363877\"><span class=\"h3\">Circulating tumor cells</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Techniques for identifying circulating tumor cells (CTCs) in peripheral blood can be modified for CSF samples with high sensitivity and specificity for epithelial tumors [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/67-70\" class=\"abstract_t\">67-70</a>]. In a study of 51 patients with solid tumors undergoing LP for clinical suspicion of LM disease, CTCs were detected in all 15 patients who were diagnosed with LM by CSF cytology <span class=\"nowrap\">and/or</span> typical MRI findings, as well as in one additional patient with negative cytology and MRI who went on to develop typical MRI findings of LM disease six months later [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/70\" class=\"abstract_t\">70</a>]. In a larger study from the same institution, a threshold of &gt;1 CTC in CSF had a sensitivity and specificity of 93 and 95 percent for the diagnosis of LM disease compared with an integrated clinical diagnosis (requiring clinical suspicion, positive CSF cytology, <span class=\"nowrap\">and/or</span> unequivocal MRI findings) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/71\" class=\"abstract_t\">71</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DIAGNOSTIC EVALUATION</span></p><p class=\"headingAnchor\" id=\"H3473096\"><span class=\"h2\">Evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients suspected of having LM should initially undergo a complete history and physical examination. The history should pay specific attention to subtle symptoms suggestive of multifocal involvement. The physical examination should include a detailed neurologic examination, which may reveal findings not suggested by the history.</p><p>Magnetic resonance imaging (MRI) of the brain and spine should be performed in all patients with suspected LM. If a routine brain MRI is normal and clinical suspicion is high, a separate high-resolution contrast-enhanced skull base MRI may highlight subtle enhancement of the cranial nerves not appreciated on routine sequences or diagnose an alternative explanation for cranial neuropathies (eg, extensive bony disease within the skull base). Particular attention should also be given to ventricular size. MRIs should ideally be obtained prior to lumbar puncture (LP), thereby avoiding post-LP imaging artifacts that might be confused with LM. (See <a href=\"#H10\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>LP is not always necessary when there are definitive findings on imaging that establish the diagnosis. LP is essential when imaging is negative or there are concerns that the patient has elevated intracranial pressure (ICP), regardless of imaging findings. LP should be deferred in patients with large intracranial or spinal masses due to the risk of causing herniation.</p><p>Cerebrospinal fluid (CSF) should be routinely sent for cell count, differential, total protein, glucose, and cytology. CSF analysis of circulating tumor cells (CTCs) is a useful complement to cytology where available. In addition, an opening pressure should be measured to screen for elevated ICP, which may be relevant for treatment. (See <a href=\"topic.htm?path=treatment-of-leptomeningeal-metastases-carcinomatous-meningitis#H6\" class=\"medical medical_review\">&quot;Treatment of leptomeningeal metastases (carcinomatous meningitis)&quot;, section on 'Increased ICP'</a>.)</p><p class=\"headingAnchor\" id=\"H3473103\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of LM should be considered in patients presenting with multifocal neurologic signs and symptoms. As described above, the results of MRI and analysis of CSF are complementary, and the use of both increases diagnostic accuracy [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/13,39\" class=\"abstract_t\">13,39</a>]. (See <a href=\"#H7301458\" class=\"local\">'Neuroimaging studies'</a> above and <a href=\"#H7301485\" class=\"local\">'Cerebrospinal fluid'</a> above.)</p><p>In patients without a known cancer diagnosis, the diagnosis can be more difficult, and repeated LPs and sometimes open biopsy of the leptomeninges may be required to secure a diagnosis. (See <a href=\"topic.htm?path=approach-to-the-patient-with-chronic-meningitis#H9\" class=\"medical medical_review\">&quot;Approach to the patient with chronic meningitis&quot;, section on 'Role of meningeal or brain biopsy'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Various conditions can mimic the clinical presentation or magnetic resonance imaging (MRI) enhancement patterns seen in patients with LM (<a href=\"image.htm?imageKey=ONC%2F53440\" class=\"graphic graphic_table graphicRef53440 \">table 2</a>). These include metastatic disease in adjacent compartments of the nervous system (eg, base of skull, dura, or superficial brain parenchyma), infectious and autoimmune diseases affecting the leptomeninges <span class=\"nowrap\">and/or</span> nerve roots, late effects of prior treatment (eg, radiation-induced nerve root thickening <span class=\"nowrap\">and/or</span> enhancement), and imaging artifacts such as prominent meningeal vascular enhancement or postlumbar puncture (LP) changes (although this is typically dural, not leptomeningeal, enhancement) [<a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/72-75\" class=\"abstract_t\">72-75</a>]. </p><p>In a patient with widespread cancer, the differential diagnosis is fairly narrow, and the primary tasks are to localize the disease to the leptomeninges (as opposed to skull base or dura) and exclude infection in patients who are febrile <span class=\"nowrap\">and/or</span> immunocompromised by their disease or its treatment. Patients with acute bacterial meningitis are typically quite ill, rapidly symptomatic, and febrile, and it is not difficult to distinguish them from patients with LM. Similarly, patients with aseptic meningitis usually present more acutely than patients with LM and will have one or more systemic symptoms such as fever, rash, diarrhea, or malaise. If infection is suspected, cerebrospinal fluid (CSF) should be sent for routine Gram stain and culture. Additional CSF tests to consider include fungal and mycobacterial cultures, acid-fast bacilli (AFB) smear, cryptococcal antigen, and virus detection assays. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-acute-bacterial-meningitis-in-adults#H3\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of acute bacterial meningitis in adults&quot;, section on 'Clinical features'</a>.)</p><p>In a patient without cancer, a broader range of infectious and noninfectious meningitides must be considered (<a href=\"image.htm?imageKey=ID%2F76402\" class=\"graphic graphic_table graphicRef76402 \">table 3</a>). (See <a href=\"topic.htm?path=approach-to-the-patient-with-chronic-meningitis\" class=\"medical medical_review\">&quot;Approach to the patient with chronic meningitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leptomeningeal metastases (LM) are diagnosed in approximately 5 percent of patients with advanced cancer. The most common primary tumors associated with the development of LM are breast, lung, and melanoma. The incidence of LM may be increasing in cancers with improved systemic therapy options. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multifocal neurologic signs and symptoms are a hallmark of the presentation of LM. Among the most common presenting symptoms are headache, nausea and vomiting, leg weakness, ataxia, altered mental status, diplopia, and facial weakness. Seizures occur in up to one-quarter of patients. (See <a href=\"#H7302347\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Magnetic resonance imaging (MRI) of the brain and spine should be performed in all patients suspected of having LM prior to lumbar puncture (LP). Typical findings on MRI that suggest a diagnosis of LM include linear and nodular leptomeningeal enhancement; thickening and enhancement of cranial nerves or nerve roots, including the cauda equina; and hydrocephalus. A typical MRI in the appropriate clinical setting is sufficient for establishing the diagnosis without LP. (See <a href=\"#H7301458\" class=\"local\">'Neuroimaging studies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients with LM will have abnormal cerebrospinal fluid (CSF) parameters, such as mild pleocytosis, elevated total protein, decreased glucose, and elevated opening pressure. (See <a href=\"#H1009947\" class=\"local\">'Basic parameters'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The identification of malignant cells in the CSF definitively establishes the diagnosis of LM, even if the typical clinical or radiographic features are not present. However, cytology is negative in up to 20 percent of patients. Detection of circulating tumor cells (CTCs) in CSF is technically feasible at some institutions and increases sensitivity for the diagnosis of LM when combined with other tests. (See <a href=\"#H7301492\" class=\"local\">'Cytology'</a> above and <a href=\"#H363877\" class=\"local\">'Circulating tumor cells'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A positive CSF cytology is the traditional gold standard and establishes the diagnosis of LM in the majority of patients. A typical MRI in the appropriate clinical setting is also sufficient for diagnosis. (See <a href=\"#H5\" class=\"local\">'Diagnostic evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CSF flow cytometry may be particularly valuable in diagnosing LM from hematologic malignancies but is not routinely indicated for the evaluation of solid tumors. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-secondary-central-nervous-system-lymphoma#H7\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of secondary central nervous system lymphoma&quot;, section on 'Leptomeningeal metastasis'</a> and <a href=\"topic.htm?path=involvement-of-the-central-nervous-system-with-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Involvement of the central nervous system with acute myeloid leukemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated tumor marker concentrations in the CSF may be helpful in selected patients, but we do not routinely do this except in cases where the clinical suspicion is high and multiple cytologic samples are negative. (See <a href=\"#H1010278\" class=\"local\">'Tumor markers'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In exceptional cases with a negative cytology and without evidence of disseminated cancer, an open leptomeningeal biopsy may be required. (See <a href=\"#H3473103\" class=\"local\">'Diagnosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/1\" class=\"nounderline abstract_t\">Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 9:225.</a></li><li class=\"breakAll\">Posner JB. Neurologic complications of cancer, F.A. Davis, Philadelphia 1995.</li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/3\" class=\"nounderline abstract_t\">Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin 2003; 21:25.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/4\" class=\"nounderline abstract_t\">Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49:759.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/5\" class=\"nounderline abstract_t\">Yap HY, Yap BS, Tashima CK, et al. Meningeal carcinomatosis in breast cancer. Cancer 1978; 42:283.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/6\" class=\"nounderline abstract_t\">Chamberlain MC. Carcinomatous meningitis. Arch Neurol 1997; 54:16.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/7\" class=\"nounderline abstract_t\">Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol 1996; 7:773.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/8\" class=\"nounderline abstract_t\">Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996; 53:626.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/9\" class=\"nounderline abstract_t\">Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999; 25:103.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/10\" class=\"nounderline abstract_t\">DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38:245.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/11\" class=\"nounderline abstract_t\">Shapiro WR, Posner JB, Ushio Y, et al. Treatment of meningeal neoplasms. Cancer Treat Rep 1977; 61:733.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/12\" class=\"nounderline abstract_t\">Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol 1978; 19:579.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/13\" class=\"nounderline abstract_t\">Clarke JL, Perez HR, Jacks LM, et al. Leptomeningeal metastases in the MRI era. Neurology 2010; 74:1449.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/14\" class=\"nounderline abstract_t\">Lara-Medina F, Crismatt A, Villarreal-Garza C, et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J 2012; 18:233.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/15\" class=\"nounderline abstract_t\">Umemura S, Tsubouchi K, Yoshioka H, et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012; 77:134.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/16\" class=\"nounderline abstract_t\">Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012; 7:382.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/17\" class=\"nounderline abstract_t\">Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008; 10:199.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/18\" class=\"nounderline abstract_t\">Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med 1991; 115:507.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/19\" class=\"nounderline abstract_t\">Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 1991; 48:28.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/20\" class=\"nounderline abstract_t\">Altundag K, Bondy ML, Mirza NQ, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007; 110:2640.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/21\" class=\"nounderline abstract_t\">Saito R, Kumabe T, Jokura H, et al. Symptomatic spinal dissemination of malignant astrocytoma. J Neurooncol 2003; 61:227.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/22\" class=\"nounderline abstract_t\">Hukin J, Siffert J, Cohen H, et al. Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. Neuro Oncol 2003; 5:188.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/23\" class=\"nounderline abstract_t\">Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/24\" class=\"nounderline abstract_t\">Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101:810.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/25\" class=\"nounderline abstract_t\">Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005; 103:2344.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/26\" class=\"nounderline abstract_t\">Emoto S, Ishigami H, Yamaguchi H, et al. Frequent development of leptomeningeal carcinomatosis in patients with peritoneal dissemination of gastric cancer. Gastric Cancer 2011; 14:390.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/27\" class=\"nounderline abstract_t\">Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol 1997; 32:215.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/28\" class=\"nounderline abstract_t\">DeAngelis LM, Mandell LR, Thaler HT, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989; 24:798.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/29\" class=\"nounderline abstract_t\">Johnson MD, Avkshtol V, Baschnagel AM, et al. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery. Int J Radiat Oncol Biol Phys 2016; 94:537.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/30\" class=\"nounderline abstract_t\">Ahn JH, Lee SH, Kim S, et al. Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection. J Neurosurg 2012; 116:984.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/31\" class=\"nounderline abstract_t\">Suki D, Abouassi H, Patel AJ, et al. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 2008; 108:248.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/32\" class=\"nounderline abstract_t\">Suki D, Hatiboglu MA, Patel AJ, et al. Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. Neurosurgery 2009; 64:664.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/33\" class=\"nounderline abstract_t\">Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn) 2012; 18:328.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/34\" class=\"nounderline abstract_t\">Zhu JJ, Padillo O, Duff J, et al. Cavernous sinus and leptomeningeal metastases arising from a squamous cell carcinoma of the face: case report. Neurosurgery 2004; 54:492.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/35\" class=\"nounderline abstract_t\">Lossos A, Siegal T. Numb chin syndrome in cancer patients: etiology, response to treatment, and prognostic significance. Neurology 1992; 42:1181.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/36\" class=\"nounderline abstract_t\">Hansen K, Gjerris F, S&oslash;rensen PS. Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir (Wien) 1987; 86:93.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/37\" class=\"nounderline abstract_t\">Laas R, Arnold H. Compression of the outlets of the leptomeningeal veins--the cause of intracranial plateau waves. Acta Neurochir (Wien) 1981; 58:187.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/38\" class=\"nounderline abstract_t\">Klein P, Haley EC, Wooten GF, VandenBerg SR. Focal cerebral infarctions associated with perivascular tumor infiltrates in carcinomatous leptomeningeal metastases. Arch Neurol 1989; 46:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/39\" class=\"nounderline abstract_t\">Straathof CS, de Bruin HG, Dippel DW, Vecht CJ. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999; 246:810.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/40\" class=\"nounderline abstract_t\">Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38:51.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/41\" class=\"nounderline abstract_t\">Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990; 40:435.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/42\" class=\"nounderline abstract_t\">Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995; 23:233.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/43\" class=\"nounderline abstract_t\">Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol 2002; 23:817.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/44\" class=\"nounderline abstract_t\">Kleinschmidt-DeMasters BK, Damek DM. The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol 2010; 96:375.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/45\" class=\"nounderline abstract_t\">Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82:733.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/46\" class=\"nounderline abstract_t\">Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 2001; 3:42.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/47\" class=\"nounderline abstract_t\">Hauke RJ, Tarantolo SR, Bashir RM, et al. Central nervous system Hodgkin's disease relapsing with eosinophilic pleocytosis. Leuk Lymphoma 1996; 21:173.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/48\" class=\"nounderline abstract_t\">Lossos A, Siegal T. Spinal subarachnoid hemorrhage associated with leptomeningeal metastases. J Neurooncol 1992; 12:167.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/49\" class=\"nounderline abstract_t\">Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998; 50:1173.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/50\" class=\"nounderline abstract_t\">Bigner SH. Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications. J Neuropathol Exp Neurol 1992; 51:235.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/51\" class=\"nounderline abstract_t\">Hoon DS, Kuo CT, Wascher RA, et al. Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. J Invest Dermatol 2001; 117:375.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/52\" class=\"nounderline abstract_t\">Malkin MG, Posner JB. Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases. Eur J Cancer Clin Oncol 1987; 23:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/53\" class=\"nounderline abstract_t\">Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000; 54:1670.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/54\" class=\"nounderline abstract_t\">van Zanten AP, Twijnstra A, Ongerboer de Visser BW, et al. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry 1991; 54:119.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/55\" class=\"nounderline abstract_t\">Castro MP, McDonald TJ, Qualman SJ, Odorisio TM. Cerebrospinal fluid gastrin releasing peptide in the diagnosis of leptomeningeal metastases from small cell carcinoma. Cancer 2001; 91:2122.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/56\" class=\"nounderline abstract_t\">Fujimaki T, Mishima K, Asai A, et al. Levels of beta-human chorionic gonadotropin in cerebrospinal fluid of patients with malignant germ cell tumor can be used to detect early recurrence and monitor the response to treatment. Jpn J Clin Oncol 2000; 30:291.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/57\" class=\"nounderline abstract_t\">Jorda M, Ganjei-Azar P, Nadji M. Cytologic characteristics of meningeal carcinomatosis: increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 1998; 55:181.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/58\" class=\"nounderline abstract_t\">Bernstein WB, Kemp JD, Kim GS, Johnson VV. Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer. J Clin Oncol 2008; 26:3281.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/59\" class=\"nounderline abstract_t\">Cone LA, Koochek K, Henager HA, et al. Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review. Surg Neurol 2006; 65:372.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/60\" class=\"nounderline abstract_t\">Kosmas C, Tsavaris NB, Soukouli G, et al. Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer. Med Oncol 2005; 22:123.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/61\" class=\"nounderline abstract_t\">Walbert T, Groves MD. Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. Future Oncol 2010; 6:287.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/62\" class=\"nounderline abstract_t\">van de Langerijt B, Gijtenbeek JM, de Reus HP, et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 2006; 67:114.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/63\" class=\"nounderline abstract_t\">Reijneveld JC, Brandsma D, Boogerd W, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005; 65:1120.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/64\" class=\"nounderline abstract_t\">Friedberg MH, Glantz MJ, Klempner MS, et al. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998; 82:923.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/65\" class=\"nounderline abstract_t\">Katopodis N, Glantz MJ, Kim L, et al. Lipid-associated sialoprotein in the cerebrospinal fluid: association with brain malignancies. Cancer 2001; 92:856.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/66\" class=\"nounderline abstract_t\">Groves MD, Hess KR, Puduvalli VK, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 2009; 94:229.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/67\" class=\"nounderline abstract_t\">Le Rhun E, Massin F, Tu Q, et al. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol 2012; 12:21.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/68\" class=\"nounderline abstract_t\">Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al. Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol 2013; 30:538.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/69\" class=\"nounderline abstract_t\">Patel AS, Allen JE, Dicker DT, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2011; 2:752.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/70\" class=\"nounderline abstract_t\">Nayak L, Fleisher M, Gonzalez-Espinoza R, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology 2013; 80:1598.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/71\" class=\"nounderline abstract_t\">Lin X, Fleisher M, Rosenblum M, et al. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro Oncol 2017; 19:1248.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/72\" class=\"nounderline abstract_t\">Mokri B. Spontaneous intracranial hypotension. Curr Neurol Neurosci Rep 2001; 1:109.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/73\" class=\"nounderline abstract_t\">Olsan AD, Milburn JM, Baumgarten KL, Durham HL. Leptomeningeal enhancement in a patient with proven West Nile virus infection. AJR Am J Roentgenol 2003; 181:591.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/74\" class=\"nounderline abstract_t\">Hsia AW, Katz JS, Hancock SL, Peterson K. Post-irradiation polyradiculopathy mimics leptomeningeal tumor on MRI. Neurology 2003; 60:1694.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-leptomeningeal-metastases-from-solid-tumors/abstract/75\" class=\"nounderline abstract_t\">Ducray F, Guillevin R, Psimaras D, et al. Postradiation lumbosacral radiculopathy with spinal root cavernomas mimicking carcinomatous meningitis. Neuro Oncol 2008; 10:1035.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5185 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOPHYSIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL FEATURES</a><ul><li><a href=\"#H7302347\" id=\"outline-link-H7302347\">Clinical manifestations</a><ul><li><a href=\"#H3980862348\" id=\"outline-link-H3980862348\">- Headache</a></li><li><a href=\"#H1008198\" id=\"outline-link-H1008198\">- Altered mental status</a></li><li><a href=\"#H1008206\" id=\"outline-link-H1008206\">- Cranial neuropathies</a></li><li><a href=\"#H1008420\" id=\"outline-link-H1008420\">- Cerebellar dysfunction</a></li><li><a href=\"#H1649165494\" id=\"outline-link-H1649165494\">- Radiculopathy and cauda equina syndrome</a></li><li><a href=\"#H178317791\" id=\"outline-link-H178317791\">- Seizures</a></li><li><a href=\"#H4062728270\" id=\"outline-link-H4062728270\">- Plateau waves</a></li><li><a href=\"#H2330625590\" id=\"outline-link-H2330625590\">- Other symptoms</a></li></ul></li><li><a href=\"#H7301458\" id=\"outline-link-H7301458\">Neuroimaging studies</a><ul><li><a href=\"#H1357079994\" id=\"outline-link-H1357079994\">- Brain MRI</a></li><li><a href=\"#H1009758\" id=\"outline-link-H1009758\">- Spine MRI</a></li></ul></li><li><a href=\"#H7301485\" id=\"outline-link-H7301485\">Cerebrospinal fluid</a><ul><li><a href=\"#H1009947\" id=\"outline-link-H1009947\">- Basic parameters</a></li><li><a href=\"#H7301492\" id=\"outline-link-H7301492\">- Cytology</a></li><li><a href=\"#H7301581\" id=\"outline-link-H7301581\">- Flow cytometry</a></li><li><a href=\"#H1010278\" id=\"outline-link-H1010278\">- Tumor markers</a></li><li><a href=\"#H363877\" id=\"outline-link-H363877\">- Circulating tumor cells</a></li></ul></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">DIAGNOSTIC EVALUATION</a><ul><li><a href=\"#H3473096\" id=\"outline-link-H3473096\">Evaluation</a></li><li><a href=\"#H3473103\" id=\"outline-link-H3473103\">Diagnosis</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/5185|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/88981\" class=\"graphic graphic_diagnosticimage\">- Cerebellar MRI findings in leptomeningeal metastases</a></li><li><a href=\"image.htm?imageKey=RADIOL/87763\" class=\"graphic graphic_diagnosticimage\">- Sagittal brain MRI in leptomeningeal metastases</a></li><li><a href=\"image.htm?imageKey=RADIOL/88877\" class=\"graphic graphic_diagnosticimage\">- Cranial nerve enhancement secondary to leptomeningeal metastases</a></li><li><a href=\"image.htm?imageKey=RADIOL/87728\" class=\"graphic graphic_diagnosticimage\">- Hydrocephalus in leptomeningeal disease</a></li><li><a href=\"image.htm?imageKey=ONC/88980\" class=\"graphic graphic_diagnosticimage\">- Sulcal leptomeningeal metastases</a></li><li><a href=\"image.htm?imageKey=RADIOL/58160\" class=\"graphic graphic_diagnosticimage\">- Spine MRI findings in leptomeningeal metastases</a></li></ul></li><li><div id=\"ONC/5185|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/78434\" class=\"graphic graphic_figure\">- Tumor spread into leptomeningeal space</a></li><li><a href=\"image.htm?imageKey=NEURO/53006\" class=\"graphic graphic_figure\">- Cervical dermatomes</a></li><li><a href=\"image.htm?imageKey=NEURO/50419\" class=\"graphic graphic_figure\">- Lumbosacral dermatomes</a></li></ul></li><li><div id=\"ONC/5185|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/65372\" class=\"graphic graphic_picture\">- Leptomeningeal melanoma</a></li><li><a href=\"image.htm?imageKey=ONC/55757\" class=\"graphic graphic_picture\">- CSF cytology in a patient with adenocarcinoma of the lung</a></li></ul></li><li><div id=\"ONC/5185|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/81558\" class=\"graphic graphic_table\">- Cerebrospinal fluid biochemical markers</a></li><li><a href=\"image.htm?imageKey=ONC/53440\" class=\"graphic graphic_table\">- Differential diagnosis of leptomeningeal metastases</a></li><li><a href=\"image.htm?imageKey=ID/76402\" class=\"graphic graphic_table\">- Etiology of chronic meningitis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anatomy-and-localization-of-spinal-cord-disorders\" class=\"medical medical_review\">Anatomy and localization of spinal cord disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-chronic-meningitis\" class=\"medical medical_review\">Approach to the patient with chronic meningitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cerebrospinal-fluid-physiology-and-utility-of-an-examination-in-disease-states\" class=\"medical medical_review\">Cerebrospinal fluid: Physiology and utility of an examination in disease states</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-acute-bacterial-meningitis-in-adults\" class=\"medical medical_review\">Clinical features and diagnosis of acute bacterial meningitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-secondary-central-nervous-system-lymphoma\" class=\"medical medical_review\">Clinical presentation and diagnosis of secondary central nervous system lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults\" class=\"medical medical_review\">Evaluation and management of elevated intracranial pressure in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=involvement-of-the-central-nervous-system-with-acute-myeloid-leukemia\" class=\"medical medical_review\">Involvement of the central nervous system with acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-diplopia\" class=\"medical medical_review\">Overview of diplopia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=polyradiculopathy-spinal-stenosis-infectious-carcinomatous-and-inflammatory-nerve-root-syndromes\" class=\"medical medical_review\">Polyradiculopathy: Spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-leptomeningeal-metastases-carcinomatous-meningitis\" class=\"medical medical_review\">Treatment of leptomeningeal metastases (carcinomatous meningitis)</a></li></ul></div></div>","javascript":null}